Jiangsu Recbio Technology Past Earnings Performance
Past criteria checks 0/6
Jiangsu Recbio Technology's earnings have been declining at an average annual rate of -15%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 87.3% per year.
Key information
-15.0%
Earnings growth rate
-8.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 87.3% |
| Return on equity | -65.2% |
| Net Margin | -1,263.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jiangsu Recbio Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 43 | -549 | 125 | 445 |
| 31 Mar 24 | 37 | -560 | 139 | 467 |
| 31 Dec 23 | 30 | -572 | 152 | 488 |
| 30 Sep 23 | 19 | -609 | 160 | 549 |
| 30 Jun 23 | 8 | -646 | 167 | 610 |
| 31 Mar 23 | 7 | -684 | 165 | 663 |
| 31 Dec 22 | 5 | -723 | 164 | 716 |
| 30 Sep 22 | 6 | -673 | 151 | 637 |
| 30 Jun 22 | 8 | -677 | 143 | 623 |
| 31 Mar 22 | 7 | -667 | 145 | 548 |
| 31 Dec 21 | 6 | -658 | 147 | 473 |
| 30 Sep 21 | 3 | -627 | 126 | 450 |
| 31 Dec 20 | 1 | -179 | 18 | 131 |
Quality Earnings: G93 is currently unprofitable.
Growing Profit Margin: G93 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: G93 is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare G93's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G93 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: G93 has a negative Return on Equity (-65.23%), as it is currently unprofitable.